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Background: Young breast cancer (BC) patients less than 45 years old are at higher risk of dying from the disease
when compared to their older counterparts. However, specific risk factors leading to this poorer outcome have not
been identified.
Methods: One candidate is iron deficiency, as this is common in young women and a clinical feature of young
age. In the present study, we used immuno-competent and immuno-deficient mouse xenograft models as well as
hemoglobin as a marker of iron status in young BC patients to demonstrate whether host iron deficiency plays
a pro-metastatic role.
Results: We showed that mice fed an iron-deficient diet had significantly higher tumor volumes and lung
metastasis compared to those fed normal iron diets. Iron deficiency mainly altered Notch but not TGF-β and Wnt
signaling in the primary tumor, leading to the activation of epithelial mesenchymal transition (EMT). This was
revealed by increased expression of Snai1 and decreased expression of E-cadherin. Importantly, correcting iron
deficiency by iron therapy reduced primary tumor volume, lung metastasis, and reversed EMT markers in mice.
Furthermore, we found that mild iron deficiency was significantly associated with lymph node invasion in young
BC patients (p<0.002).
Conclusions: Together, our finding indicates that host iron deficiency could be a contributor of poor prognosis in
young BC patients.
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Hypoxia-inducible factorsBackground
Breast cancer (BC) patients diagnosed at < 45 years old
have lower survival and higher recurrence rates when
compared to their older counterparts. Cancers in these
young patients are more likely to be of a higher histo-
logical grade and more readily metastasize to other
organs [1,2]. The specific risk factors contributing to
this poorer outcome have not been identified. Although
a decline in total BC cases was recently reported, a plot
of age-specific BC rates shows a decrease only in older
women (≥ 45 years old), [3] suggesting that recent* Correspondence: Xi.Huang@nyumc.org
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reproduction in any medium, provided the oradvances in BC research have just benefited older
patients [4]. There is an urgent need to study young BC
because despite poor prognosis in young patients, treat-
ment options are the same as they are for older patients.
This dilemma calls for new research to identify poor
prognostic factors that specially belong to young women.
The differences in clinical outcomes between young
and older patients cannot be fully explained by estrogen
status and/or family history [5,6]. Studies in BC risk
factors and tumor characteristics indicate that young BC
patients have an additional disease entity that is unique
to them [2,7]. A typical characteristic of young pre-
menopausal women is the menstrual cycle. Because of
menstruation, iron deficiency is highly prevalent in
young women, particularly in poorer, less educated, and
minority populations [8,9]. Interestingly, these populations. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This suggests that iron deficiency may be a risk factor in
BC agressiveness of young patients, but its role has not
been investigated to date.
The well-established “seed and soil” theory indicates
that host responses are equally important as intrinsic
properties of cancer cells in determining cancer outcomes
[11]. For example, increasing evidence has demonstrated
that iron has a role in the tumor microenvironment and
pathways of iron acquisition, efflux, and regulation are all
perturbed in cancer [12]. This suggests that reprograming
of iron metabolism, either through iron responsive elem-
ent/iron regulatory proteins or hepcidin/ferroportin axis
or some unidentified mechanisms, is a central aspect of
tumor cell survival [12] In distinction to increased iron in
cancer cells and its microenvironment, we previously
hypothesized that host iron deficiency and macro-
environment as a young women-specific risk factor results
in increased susceptibility of young patients to BC metas-
tasis and recurrence [13] Here we expand on this study
and show that host iron deficiency promotes mammary
cancer growth and metastasis in mice and is a significant
predictor of lymph node invasion in humans.Methods
Cell line and reagents
To avoid confounding factors such as estrogen, ER, PR,
and Her2 negative human BC MDA-MB-231 and mouse
mammary cancer 4T1 cell lines (ATCC, Manassas, VA)
were used. Antibodies were: E-cadherin and Twist1 (Santa
Cruz Biotechnology, Santa Cruz, CA); α-tubulin and Snai1
(Cell Signaling, Danvers, MA); Snai1 for immunofluores-
cence (Abcam, Cambridge, MA); Notch2 (Sigma Chem-
ical Co., St. Louis, MO); and Alexa-488 labeled donkey
anti-rabbit antibody (Invitrogen, Carlsbad, CA).Iron deficient mouse tumor xenograft models
All animal experiments were performed according to the
protocol approved by the Institutional Animal Care and
Use Committee at the New York University School of
Medicine. The key to successfully induce iron deficiency
in mice is to start the special diet at early age [14].
In the present study, 3-week-old immune-competent
Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were
used. After randomly dividing into three groups, thirty
mice were fed diets containing 3.5 ppm, 35 ppm, or 350
ppm ferrous sulfate, respectively. The diet was based on
a commercial iron deficient AIN-93G purified rodent
diet, which was found to contain 2 mg Fe per kg diet (2
ppm) [15]. The diets with different concentrations of
ferrous sulfate were prepared by Dyets Inc. (Bethlehem,
PA) and shipped to the laboratory. Upon receipt, iron
concentrations and its availability were analyzed byferrozine assay as previously described [16] and they all
met the required specifications.
After 12 weeks, mice from each diet group were sub-
cutaneously (s.c.) inoculated with 5 × 104 4T1 cells into
the flanks (suspended in 0.1 ml PBS). Tumor volumes
were measured twice weekly. Mice were sacrificed four
weeks later and primary tumors, lung, and liver were
collected. Each primary tumor was divided into three
parts for RNA isolation, protein extraction, and hist-
ology, respectively. The upper lobe of the left lung was
fixed in Bouin’s solution and lung metastases were
quantitated by counting the numbers of tumor nodules
on the surface.
To verify whether iron deficiency promotes tumor
growth in human BC cells, twenty 3-week-old immuno-
compromised non-obese diabetic/severe combined im-
mune-deficient (NOD/SCID) mice were fed a special
gamma irradiation-treated diet containing either 3.5
ppm or 350 ppm iron (Dyets Inc., Bethlehem, PA) for 12
weeks. After inoculating 1 × 106 MDA-MB-231 cells into
the mammary fat pads, tumor volumes were measured
as described for 4T1 cells.
RNA isolation and quantitative PCR (qPCR)
RNA from primary tumors was extracted in TRIzol
(Invitrogen, Carlsbad, CA) and 10 μg RNA from each
homogenate were pooled to represent the average ex-
pressions of the group. 2 μg pooled RNA were reverse-
transcribed by Superscript® III RT (Invitrogen, Carlsbad,
CA) [17]. The sequences of the primers are listed in
Additional file 1: Table S1 and the mRNA expression
levels of the target genes were normalized to the
geomean of three housekeeping genes, GAPDH, G6PD,
and HPRT1 and then expressed as fold changes over the
mice fed 350 ppm iron diet.
Protein extraction and Western blot
Primary tumor tissues were homogenized in RIPA lysis
buffer containing proteinase inhibitors. 100 μg proteins
were taken from each mouse and combined into one
sample as representative of each group. Equal amounts
of the pooled proteins were loaded onto 8-12% SDS-
polyacrylamide gels. After transferring, PVDF mem-
branes were first probed with primary antibodies,
followed by HRP-labeled secondary antibody, and visual-
ized by enhanced chemiluminescence kit (PerkinElmer,
Waltham, MA).
Immunofluorescence staining and immunohistochemistry
Fixed tumor tissues embedded in paraffin were sequen-
tially cut into 6 μm sections and mounted onto slides.
Slides were deparaffinized in xylene and hydrated with
gradient ethanol. Antigen retrieval was performed with
0.1% trypsin. The slides were blocked in 1% BSA and
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was used as negative control, and Snai1, E-cadherin, and
Notch2 antibodies with various dilutions were added to
the slides, detected with Alexa-488 labeled donkey anti-
rabbit antibody and, imaged by a Leica TCS SP5 con-
focal system.
Immunohistochemistry for ferritin was performed on a
NEXes automated stainer (Ventana Medical Systems,
Tucson AZ). Heat antigen retrieval was performed in
0.01M citrate. Rabbit anti-mouse ferritin (Abcam,
Cambridge MA) was diluted 1:500, detected with
biotinylated goat anti-rabbit (Vector Laboratories
Burlingame, CA) and, visualized with streptavidin-HRP and
diaminobenzidene. Slides were counterstained with hema-
toxylin. Snail was studied similarly with a 1:200 dilution.
Iron therapy assay
Thirty 3-week-old Balb/c mice were randomly divided
into three groups. One group (10 mice) was fed 350
ppm iron and the other two groups were fed 3.5 ppm
iron. After 11 weeks, each mouse from one group of
iron deficient mice received an intraperitoneal (i.p.)
injection of 0.5 mg iron dextran (100 mg/ml Fe, Sigma-
Aldrich, St. Louis, MO), which is a clinically relevant
dose equivalent to a human dose of 1.0 g per 60 kg, [18]
since a mouse weighs about 30 g. The diet for this group
was then switched to 350 ppm iron diet. One week later,
all mice were inoculated with 5 × 104 4T1 cells into
mammary fat pads. Tumor volumes were measured and
tissue samples were collected and processed.
Association of hemoglobin with lymph node status in
young BC patients
Through the Department of Pathology at the Fourth
Military Medical School in Xi’an, China, there were a
total of 148 BC patients < 45 years old diagnosed be-
tween year 2008 and year 2010 (Additional file 2: Table
S2). Because ferritin and transferrin saturation were not
available, hemoglobin (Hb) levels were used to compare
between lymph node positive and negative groups.
Patients’ personal information was recorded in such a
manner that subjects cannot be identified directly or
through identifiers linked to the subjects. This study is
exempted from the Institutional Review Board (IRB) by
the Fourth Military Medical University. Age, hemo-
globin levels, and lymph node status at the time of
diagnosis were used.
Statistical Analyses
Statistical evaluations of the mouse data were conducted
by Student's t-test for paired comparison or by one-way
analysis of variance for multiple comparisons, followed
by a post hoc Newmann-Keuls test. p-value < 0.05 was
considered to be significantly different. For human data,Wilcoxon test was used to compare Hb levels between
node positive and node negative groups, and boxplots
were used to demonstrate the distributional difference
between the two groups. Logistic regression with node
positivity as response and Hb levels and age as predic-
tors was used to assess association of Hb levels with
lymph node positivity.
Results
Effects of iron deficiency on tumor growth and metastasis
Previous studies have shown that, despite a 10-fold
spread in iron contents from each diet, mice fed 35 ppm
and 350 ppm iron have normal iron status and those fed
3.5 ppm iron are iron deficient [14,19]. Here mild iron
deficiency was observed in Balb/c mice fed 3.5 ppm iron
as reflected by a transferrin saturation of < 20% and
lowered serum iron. Mice fed 35 ppm and 350 ppm iron
had adequate iron status (Additional file 3: Figure S1).
Subsequently, these mice were inoculated with 4T1
cells into the right flank. From day 18, primary tumor
volumes were significantly higher in iron deficient mice
compared to the two groups of mice fed normal iron
diets (2922.6 ± 161.8 mm3 in 3.5 ppm Fe vs 1636.5 ±
86.6 mm3 in 35 ppm Fe, or 1453.8 ± 90.6 mm3 in 350
ppm Fe, mean ± SEM, p < 0.05, n=9) (Figure 1A).
To investigate whether this observation is true with
human BC cells, NOD/SCID mice were fed 3.5 and 350
ppm iron for 12 weeks, followed by s.c. injection of
1 × 106 human BC MDA-MB-231 cells into the mammary
fat pads. Figure 1B shows that primary tumor volumes
from these human cancer cells were also significantly
higher in iron deficient mice. Because of injection of
tumor cells into the mammary fat pads, tumor volumes
from MDA-MB-231 cells were smaller than those from
4T1 cells injected into the flanks of the mice.
In addition, surface lung metastases were significantly
greater in the iron deficient Balb/c mice, with approxi-
mately 22.9 ± 2.6 nodules per lobule in 3.5 ppm Fe vs
13.9 ± 2.4 in 35 ppm Fe, or 13.7 ± 2.7 in 350 ppm Fe
(p < 0.05, n=9, Figure 1C). Bousin’s staining demon-
strated that the entire lung was significantly invaded by
4T1 tumors in iron deficient mice and fewer tumor me-
tastasis to the lung were observed in mice fed normal
iron diets (Figure 1D). These results indicate that iron
deficiency promotes growth and metastasis of BC of
both mouse and human origins.
Effects of iron deficiency on epithelial mesenchymal
transition (EMT)
To explore molecular mechanisms by which iron defi-
ciency potentiates metastasis, we searched EMT markers
[20]. EMT is characterized by decreases in epithelial
markers, such as E-cadherin, which is driven by tran-
scription repressors, such as Snail, Twist and Zeb [21].
Figure 1 Host iron deficiency promotes mouse mammary tumor and human BC growth and metastasis. (A) Balb/c mice were fed
standard rodent diets containing 3.5 ppm Fe (iron deficient), 35 ppm Fe (normal low), and 350 ppm Fe (normal high), respectively. After 12
weeks, 5 × 104 mouse 4T1 mammary cancer cells were subcutaneously (s.c.) injected into the flanks of the mice. (B) NOD/SCID mice were fed 3.5
ppm and 350 ppm Fe diets. After 12 weeks, 1 × 106 human BC MDA-MB-231 cells were s.c. injected into mammary fat pad. (C) Average number
of tumor nodules per lobe of the lung in each diet group from the 4T1/Balb/c mouse model. (D) Representative metastatic lungs from each diet
group of the 4T1/Balb/c mouse model. Arrow indicates tumor nodules. *: Significantly different from the group of mice fed 350 ppm Fe diet.
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iron deficient mice, as mRNA levels of Snai1, 2 and
Zeb1, 2 were upregulated at least one-fold in the primary
tumors of mice fed an iron deficient diet (Figure 2A).
Consistent with qPCR results, protein levels of E-cadherin
were dramatically decreased but levels of Snai1 were
greatly augmented by iron deficiency (Figure 2B). Ferritin,
an iron storage protein, was low in the primary tumors
from mice fed iron deficient diet. Immunofluorescence
showed an iron dose-dependent decrease in Snai1 expres-
sion (Figure 2C).Effects of iron deficiency on Notch, TGF-β, and WNT
signaling
To determine which pathway is responsible for iron
deficiency-mediated EMT, we examined changes in
transforming growth factor-beta (TGF-β), wingless-int
(WNT), and Notch signaling [22, 23]. We found that
mRNA levels of Notch 2, 3, and 4 and their ligands
Jagged1, 2 and Hes1 were increased approximately 1–4
folds in primary tumors from iron deficient mice
(Figure 3A). There were no significant differences in
mRNA levels of TGF-β and WNT signaling pathways
among the three diet groups (Figure 3B and 3C). These
results suggest that host iron deficiency mainly alters
Notch signaling, leading to EMT activation.Effects of iron supplementation on EMT and tumor
growth and metastasis
To show that iron deficiency is responsible for the ob-
served tumor growth and metastasis, we reversed iron
deficiency by injecting iron dextran one week before
tumor xenograft. Using immunohistochemistry (IHC),
we found that iron dextran replenished iron levels. Strik-
ing differences in liver ferritin exist between iron-
deficient mice and iron-deficient mice receiving iron
treatment or mice fed normal iron diet (Figure 4A; left
column). Differences in ferritin levels in the primary tu-
mors between iron-deficient mice and mice fed normal
iron or receiving iron supplement were not as striking
(Figure 4A). We also found that iron deficient mice have
higher tumor volume than mice fed normal iron diet
(925.6 ± 147.4 mm3 vs. 644.8 ± 53.2, p < 0.05, n=9).
Most importantly, iron therapy significantly inhibited
iron deficiency-related tumor growth (638.8 ± 90.3 vs.
925.6 ± 147.4 p < 0.05, n=9) (Figure 4B). While iron
deficiency enhanced lung metastasis, iron therapy de-
creases lung metastasis (Figure 4C). In this experiment,
instead of injecting 4T1 cells into the flanks (Figure 1A),
they were injected into the mammary fat pads, resulting
in smaller tumor volumes and less numbers of lung
metastasis.
Not only did iron therapy reverse lung metastasis, but
also reversed iron deficiency-mediated tumor growth
Figure 2 Host iron deficiency activates EMT pathway. (A) The mRNA expression profiles for EMT markers were normalized to the geomean of
three housekeeping genes, GAPDH, G6PD, and HPRT1 and expressed as fold changes over the control mice fed 350 ppm Fe diet. (B) Alteration of
E-cadherin, Snai1, Twist1, and ferritin proteins in primary tumors of mice fed iron-deficient diet. α-tubulin was used as a loading control. (C)
Increased expression of Snai1 in primary tumors of mice fed iron-deficient diet by immunofluorescence. Tumor tissues were stained with normal
rabbit IgG (control) or Snai1 antibody (Green) and DPAI (Blue). *: Significantly different from the group of mice fed 350 ppm Fe diet.
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E-cadherin (Figure 5C), and decreased Notch2 expression
(Figure 5D). These results strongly indicate that iron defi-
ciency leads to tumor growth and metastasis.
Association of hemoglobin (Hb) with lymph node
invasion in young BC patients
To show that the above observation is clinically relevant,
Hb levels were used to compare between node positive
and node negative patients. We found that Hb level is
significantly lower (p<0.002) in node positive BC pa-
tients (n=62, mean age: 34.5 years old, mean Hb ± SD:
119.6 ± 14.5 g/l, 95% CI: 116, 123.2) than node negative
BC patients (n=74, mean age: 35.5 years old, mean Hb ±
SD: 126.7 ± 13.6 g/l, 95% CI: 123.6, 129.8) (Figure 6).
Discussions
Iron is long known to be a double-edged sword. Previous
studies have shown that iron-accumulation-associatedpro-oxidant conditions in cancer cells could fuel the activ-
ity of iron-dependent proteins and enable enhanced can-
cer cell proliferation, contributing to both tumor initiation
and tumor growth [12]. In the present study, we provide
evidence that host iron deficiency-mediated proangiogenic
environment could lead to xenografted tumor growth and
metastasis as well. Although our study is limited to BC,
which has the most epidemiological data on recurrence in
young patients, it confirms previous observation that re-
currence of other cancers, such as colorectal cancer, tends
to have a higher incidence of recurrence in young patients
[24]. By linking young age to iron deficiency and then to
BC malignancy, our finding may have identified that host
iron deficiency represents a clinical entity that is specific
to young women and is associated with lower survival and
higher recurrence in young BC patients. In support of our
view, microarray data from two age-specific cohorts
(young, ≤ 45 years, and older, ≥ 65 years) found major
gene sets unique to breast tumors in young women. These
Figure 3 Host iron deficiency stimulates Notch but not TGF-β, and Wnt signaling. (A) Iron deficiency increased mRNA expression of Notch
2, 3, 4, their receptors Jagged 1, 2 and Hes1 by qPCR. (B) No significant changes for TGF-β signaling pathway components, TGF-β1, Smad 2, and
Smad3. (C) No significant changes for Wnt signaling pathway components, LRP5, LRP6, and Wnt3a. *: Significantly different from the group of
mice fed 350 ppm Fe diet.
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cancer angiogenesis and metastasis [1]. In contrast, no
common gene sets were found among tumors arising in
older women. By comparing the gene expression profile
from young BC patients to those from mice fed iron
deficient diet, [1,13] overlaps of genes centered on hyp-
oxia, angiogenesis, and metastasis. This supports our
finding that a link may exist between host iron defi-
ciency and BC malignancy [25].
Moreover, “functional” iron deficiency known as
anemia of chronic disease (ACD) is a clinical condition
where stored iron is sufficient but circulating iron is
deficient. ACD is a well-established risk factor for in-
creased morbidity and mortality of late stage cancer
patients [26-28]. It develops as cancer progresses or
when cancer patients undergo chemotherapy. “Absolute”iron deficiency refers to the depletion of iron stores in
the body and is highly prevalent in young women as
results of menstruation and insufficient dietary iron up-
take [8,9]. If ACD increases mortality in cancer patients,
“absolute” iron deficiency could have the same effects.
Indeed, our animal data showed that mice fed 3.5 ppm
iron had a transferrin saturation of < 20%, [19] character-
izing a mild iron deficiency. This moderate iron deficiency
significantly affected tumor growth and metastasis in
both immuno-competent and immuno-deficient mice.
Furthermore, human studies suggest that mild iron de-
ficiency without advancing to anemia could be a cause
of lymph node invasion, because Hb levels in the node
positive BC patients were only slightly below normal
(119.6 g/L compared to cutoff value of 120 g/L) and
iron deficiency proceeds anemia in young women.
Figure 4 Iron therapy improves iron deficiency and decreases tumor growth and metastasis. (A) Immunohistochemistry of ferritin showed
that iron therapy replenished iron in liver and corrected iron-deficient status in Balb/c mice fed iron-deficient diet, magnification x20; (B) Iron
therapy inhibited tumor growth and (C) lung metastasis.
Figure 5 Iron therapy reverses iron deficiency-mediated EMT markers. (A) Representative primary tumors from each group; (B) Iron therapy
downregulates Snai1 to the levels in mice fed normal 350 ppm iron diet by immunohistochemistry; (C) Iron therapy upregulates E-cadherin and
(D) reduces Notch2 when compared to mice fed iron deficient diet by immunofluorescence.
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Figure 6 Association of hemoglobin (Hb) levels with lymph
node status in young BC patients. The cohort included 62
subjects with lymph node invasion (mean age 34.5 years) and 74
subjects without lymph node invasion (mean age 35.4 years). Mean
levels of Hb in patients with lymph node invasion were 119.6 g/l
and those without lymph node invasion were 126.7 g/l (p < 0.002).
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physical translocation of a cancer cell to a distant organ
and the ability of the cancer cell to develop a metastatic
lesion at the distant site [20]. EMT pushes cancer cells
to undergo changes from epithelial to mesenchymal
phenotype. We found that primary tumors grown in iron
deficient mice were characterized by decreased expres-
sion in E-cadherin and increased expression in Snai1. In
addition, Notch, but not TGF-β or WNT pathway, was
affected, suggesting that iron deficiency-mediated Notch
signaling is a likely driving force for this event. In view
of the importance of iron deficiency in hypoxia inducible
factor-1alpha (HIF-1α) stabilization and the role of HIF-
1α in Notch signaling, [29,30] iron deficiency-mediated
HIF-1α is a relevant pathway to be investigated in the
future.To further confirm that iron deficiency is a causative
factor of BC growth and metastasis, we corrected iron
deficiency by injecting iron dextran before inoculation of
cancer cells in mice. Iron supplementation replenished
iron in the liver. Most importantly, it not only reduced
tumor growth and lung metastasis, but also reversed
iron deficiency-mediated upregulation of Snai1 and
Notch and downregulation of E-cadherin.
Iron supplementation is a standard therapy to correct
iron deficiency. However, the suitability of iron therapy
for young BC patients needs further investigation. Our
study is designed to prove that iron deficiency leads to
BC aggressiveness and, thus, we used a protocol to cor-
rect iron deficiency before inoculation of cancer cells. It
remains unknown how cancer cells would respond to
iron treatment when iron is administrated after cancer
cell inoculation. To indicate the utility of iron supple-
mentation during chemotherapy, it has been shown that
amenorrhea (no menstruation) for at least six months
significantly increases overall survival in young BC pa-
tients, regardless of chemotherapy and estrogen receptor
status [31]. The average blood loss during menstruation
is 35 mL per month [32] and every 100 mL blood con-
tains about 50 mg of iron [33]. We estimate that iron
loss for a period of 6 months is in the amount of 105
mg (35 mL/month × 6 months × 50 mg/100mL). We
wonder whether 105 mg iron supplementation during
chemotherapy could increase the overall survival in
young BC patients with menses. As of now, in clinical
practice in oncology, evaluation of iron deficiency is usu-
ally not required during BC diagnosis and, thus, not
treated during BC therapy. Although clinical trial with
iron supplementation in young BC patients requires a
further high level of preclinical evidence, this research
adds one more reason for practitioners to check whether
iron levels in young BC patients are up to their FDA-
recommended levels.Conclusions
In the present study, we showed that iron deficiency,
highly prevalent in young women because of the men-
struation, could contribute to poor prognosis in young
BC patients. By linking young age to iron deficiency and
then to BC malignancy, our study may have identified
iron deficiency as a clinically treatable risk factor for
young BC patients.Additional files
Additional file 1:Table S1. The primer sequences of the
oligonucleotides used for qPCR.
Additional file 2: Table S2. Hemoglobin and lymph nodes status in
human breast cancer patients.
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different levels of iron diets. Serum iron and transferrin saturation (TS)
rate in mice fed 3.5 ppm iron diet (iron deficient), 35 ppm and 350
ppm iron diets (normal low and normal high iron levels.
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